Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Keryx selects John Neylan for newly created CMO role |
||||||||||||||||||||
Keryx Biopharmaceuticals ($KERX) appointed Dr. John Neylan to the newly created position of chief medical officer; he'll be responsible for oversight of medical affairs, clinical development and pharmacovigilance. Neylan, a nephrologist and transplantation specialist, has broad-based experience in therapeutic development, Keryx said in its release, ranging from the preclinical phase to postmarketing development. He most recently worked at Genzyme where he served as senior vice president of clinical development. He's also worked at Wyeth and held several positions in academia. "It is my pleasure to welcome John to Keryx," said Greg Madison, president and chief operating officer of Keryx. "As a nephrologist with extensive clinical development experience, John will be an invaluable member of the Keryx leadership team as we work to fulfill our vision of building a leading renal franchise." Release
|